Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$11.81M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
694.3%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$10.48M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$10.69M

Stock Price

Loading...
Market Cap: $3.4976 Million

About Azitra Inc

Azitra Inc (AZTR) is a clinical-stage biopharmaceutical company. The filing excerpts provided do not contain sufficient detail to describe its core business activity, revenue model, competitive position, or financial metrics with the specificity required. The excerpts consist solely of boilerplate SEC cover-page language and do not disclose product names, pipeline assets, revenue figures, customer information, geographic footprint, leadership, or founding history. No defensible business description can be constructed from the available filing content.

Source: SEC 10-K, filed 2026-02-27

Industry: Pharmaceutical Preparations Peers: Alzamend Neuro Inc Candel Therapeutics Inc Coya Therapeutics Inc Senti Biosciences Inc Harpoon Therapeutics, Inc. EOM Pharmaceutical Holdings, Inc. IN8bio Inc Palatin Technologies Inc Synlogic Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support